Is Olympus Corp - ADR (OLYMY) Stock a Good Investment?
Learn more about Olympus Corp - ADR's (OLYMY) stock grades for Momentum and determine whether this Advanced Medical Equipment & Technology stock meets your investment needs.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, “Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
Commentary & Analysis
Financial Summary
| Share Statistics | OLYMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13,970.7 | $416.1 | 82% |
|
| Shares Out (Mil) | 6.9 | 41.6 | 17% |
|
| Institutional Ownership | 50.0% | 83.1% | 30% |
|
| Float (Mil) | 1,041.0 | 35.6 | 91% |
|
| Beta | 0.21 | 0.88 | 13% |
|
| Avg Daily Volume (000s) | 78 | 333 | 33% |
|
| Price Change (52-week) |
8.3% | 65.0% | 54% |
|
| Growth | OLYMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.8%) | 11.8% | 15% |
|
| Net Income (5yr) | 29.7% | (5.9%) | 84% |
|
| EPS (5yr) | 33.4% | 10.2% | 84 |
|
| Dividends (5yr) | 11.7% | 0.0% | 59% |
|
| Cash Flow (5yr) | (27.4%) | (15.6%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | OLYMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6,356 | $119 | 78% |
|
| Net Income (TTM) (Mil) | $429 | ($9) | 77% |
|
| EPS (TTM) | $0.386 | ($0.400) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $633 | ($3) | 74% |
|
| Net Cash Flow (TTM) (Mil) | ($161) | $1 | 11% |
|
| Long-Term Debt (Q1) (Mil) | $1,004 | $22 | 66% |
|
| Enterprise Value (Q1) (Mil) | $10,632 | $371 | 75% |
|
| Valuation | OLYMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.00 | na |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | OLYMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.7% | 58.5% | 77% |
|
| Net Margin | 7.5% | (6.9%) | 56% |
|
| ROA | 4.6% | (13.4%) | 69% |
|
| ROE | 8.8% | (13.6%) | 53% |
|
| Liabilities to Assets | 47.2% | 46.1% | 39% |
|
| F-Score | na | 4 | na |
|
Olympus Corporation did not pass any screens on 9/2/2026.
